MDHearing VoltMax vs Signia Pure C&G IX

The MDHearing VoltMax is a behind-the-ear OTC hearing aid priced at $699, earning a B grade with a SoundScore of 3.0/5 in our lab testing. This mid-priced device ranks #62 of 65 in the OTC Hearing Aid category, placing it in the bottom portion of tested products. In our standardized testing, the VoltMax demonstrates excellent feedback handling at 5.0/5, scoring 0.46 points above the category average. This means users are unlikely to experience whistling or squealing during typical wear. However, speech performance presents significant challenges—speech in quiet scores a low 1.9/5 (0.93 points below average), while speech in noise scores 1.0/5 (0.48 points below average). These results suggest limited benefit for understanding conversation in both calm and challenging listening environments. Music streaming is a notable weakness, scoring 0.0/5 and falling 1.92 points below the category average. Users who prioritize streaming audio content from their phones should consider alternatives. Own-voice comfort is mixed at 2.4/5, roughly matching the category average. At this price point, several alternatives offer substantially stronger performance. Devices like the Yeasound RIC800 and Sony CRE-E10 score above 4.5/5 at similar or lower prices. The VoltMax may appeal to users who prioritize feedback-free wear and basic amplification with rechargeable convenience, but those seeking stronger speech clarity should explore higher-performing options in this price range.

The Signia Pure C&G IX is a premium prescription behind-the-ear hearing aid released in 2023, currently available at $3,298. In HearAdvisor's lab testing, it earned an A grade with a SoundScore of 4.1/5, ranking #20 among 36 prescription hearing aids tested. This device demonstrates consistent strength across multiple performance areas. Speech in quiet scored a solid 4.0/5, sitting 0.65 points above the category average. Speech in noise performance, while above the category average by 0.25 points, remains mixed in absolute terms at 2.2/5—a common challenge across prescription devices. Feedback handling is a standout feature, achieving a perfect 5.0/5 and exceeding the already-high category average. Own-voice comfort scores a solid 3.2/5, running 0.45 points above the category average, which suggests good occlusion management. Music streaming performs solidly at 3.0/5, also above average for the category by 0.36 points. The device supports both iPhone and Android streaming along with hands-free functionality. Professional tuning yields meaningful improvement, with the normalized score increasing from 4.0/5 to 4.5/5. Buyers seeking top-tier performance in this price range should note that competitors like the Phonak Sphere Infinio (5.0/5) and Oticon Intent (4.85/5) scored higher in our testing. The Pure C&G IX may suit those who prioritize reliable feedback control and balanced everyday performance over maximum speech-in-noise capability.